Monthly Archives: August 2022

August 17, 2022

Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry

2024-07-19T22:18:13-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Manuscript Published in Bioconjugate Chemistry2024-07-19T22:18:13-04:00
August 3, 2022

Advanced Proteome Therapeutics Receives Issued Patent

2024-07-19T22:18:14-04:00

Advanced Proteome Therapeutics Corporation (“APC” or the “Company”) (TSXV: APC) (FSE: 0E8), reports that its US subsidiary, Advanced Proteome Therapeutics Inc. (“APTI”), is dedicating additional resources to its SARS-CoV-2 protease inhibitor program.

Advanced Proteome Therapeutics Receives Issued Patent2024-07-19T22:18:14-04:00
Disclaimer: This website contains historical and forward-looking statements. The forward-looking statements involve risks and uncertainties. Forward looking statements appearing on this website in this presentation represent management's current estimates at the time they were posted and these may change significantly as new information comes to hand. The information contained in this website has been obtained by Advanced Proteome Therapeutics Incorporated from its own records and from other sources believed to be reliable; however, no representation or warranty is made as to its accuracy or completeness.

© Copyright 2015 -    |   Web Design by APM Solutions   |   All Rights Reserved
Go to Top